Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

Presentation TCT 2025

TCT 461: Long-Term Outcomes of a Sirolimus-Eluting Balloon in Femoropopliteal Lesions: 36-Month Stratified Analysis by Lesion Location from the SELUTION SFA Japan Study

Presenter: Osamu Iida

October 26, 2025

Presentation TCT 2025

TCT 464: Comparative Effectiveness and Safety of Low-Dose versus High-Dose Paclitaxel Drug-Coated Balloons for Femoropopliteal Artery Disease: One-Year Results from the DCB-SFA Randomized Trial

Presenter: Seung-Whan Lee

October 26, 2025

Presentation TCT 2025

CFA: Is it Still Surgery First?

Presenter: Matthew T. Menard

October 26, 2025

Presentation TCT 2025

Long Segment SFA Disease – Surgery vs. PTAB

Presenter: Ehrin J. Armstrong

October 26, 2025

Presentation TCT 2025

Prepping the SFA with IVL vs. Atherectomy – 2025 State of the Art

Presenter: Brian G. DeRubertis

October 26, 2025

Presentation TCT 2025

Does the SIRONA Trial Answer Our Questions about Sirolimus in the SFA?

Presenter: Dierk Scheinert

October 26, 2025

Presentation TCT 2025

Landscape of Drug Eluting Technology for SFA

Presenter: Aloke Finn

October 26, 2025

Advertisement

TCT 461: Long-Term Outcomes of a Sirolimus-Eluting Balloon in Femoropopliteal Lesions: 36-Month Stratified Analysis by Lesion Location from the SELUTION SFA Japan Study

TCT 464: Comparative Effectiveness and Safety of Low-Dose versus High-Dose Paclitaxel Drug-Coated Balloons for Femoropopliteal Artery Disease: One-Year Results from the DCB-SFA Randomized Trial

CFA: Is it Still Surgery First?

Long Segment SFA Disease – Surgery vs. PTAB

Prepping the SFA with IVL vs. Atherectomy – 2025 State of the Art

Does the SIRONA Trial Answer Our Questions about Sirolimus in the SFA?

Landscape of Drug Eluting Technology for SFA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content